Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Antifungal Antibiotic/Complex III Inhibitor
Myxothiazol is an antifungal antibiotic that acts as an inhibitor of mitochondrial electron transport chain complex III (bc1 complex). It demonstrates potent antifungal activity against various yeasts and fungi, exhibiting effective growth inhibition at concentrations ranging from 0.01 to 3 μg/ml. This compound is valuable for research applications focused on mitochondrial function and the mechanisms of antifungal resistance. -
β-1,3-Glucan Inhibitor
Ibrexafungerp is an orally active β-1,3-glucan synthesis inhibitor with demonstrated antifungal properties. Its mechanism targets the cell wall biosynthesis pathway of fungi, making it valuable in research on Candida and Aspergillus infections. This compound is a promising candidate for studies focused on antifungal resistance and the development of new antifungal therapies. -
HBV Inhibitor
HBV-IN-23 is a potent inhibitor of Hepatitis B virus (HBV) DNA replication with an IC50 of 0.58 μM. This compound effectively inhibits HBV replication across both sensitive and resistant strains. Additionally, HBV-IN-23 demonstrates anti-hepatocellular carcinoma activity by inducing apoptosis in HepG2 cells, making it a valuable tool for research into HBV and related hepatic conditions. -
Parasite Inhibitor
Quinacrine acetate is a potent modulator of the cGAS-STING-TBK1 signaling pathway, exhibiting notable immune stimulatory activity. This compound has been investigated for its therapeutic potential in enhancing anti-tumor immunity and improving the efficacy of cancer immunotherapies by addressing the immunogenicity challenges faced by various tumors. Quinacrine acetate also represents a promising approach to mitigate the limitations associated with immune checkpoint inhibitors in cancer treatment. -
Antibacterial Agent/eEF2K Inhibitor
Cefatrizine is a broad-spectrum cephalosporin antibiotic that primarily targets bacterial infections while also acting as an eEF2K inhibitor. This compound exhibits anti-proliferative activity in human breast cancer cells, inducing endoplasmic reticulum stress and subsequent cell death. Cefatrizine is a valuable reagent for research applications in understanding mechanisms of cancer therapy and exploring antibacterial efficacy. -
Ras Inhibitor
(-)-Rasfonin is a natural fungal secondary metabolite that acts as an inhibitor of small G protein Ras. It exhibits significant biological activities, including the induction of apoptosis, necrosis, and autophagy in ACHN cells, a renal carcinoma cell line. This compound is instrumental for research focused on cellular death pathways and therapeutic strategies targeting Ras-mediated signaling in cancer. -
β-lactamase Inhibitor
RDR 02308 is a β-lactamase inhibitor that targets the TLR4-MyD88 signaling pathway. This compound effectively inhibits the activity of full-length β-lactamase, providing a valuable tool for studies related to antibiotic resistance. Its mechanism of action makes it suitable for research applications focused on bacterial infections and the development of novel therapeutic strategies. -
Superoxide Anion Inhibitor
Tanzawaic acid B is a potent inhibitor of superoxide anion production, derived from the fungal source Penicillium citrinum. This compound has been demonstrated to mitigate oxidative stress by targeting superoxide radicals, making it valuable for research in oxidative damage and related pathologies. Its biological activity provides a useful tool for studying the effects of reactive oxygen species in various cellular models. -
HIV-1 RT Inhibitor
Apricitabine is a selective inhibitor of HIV-1 reverse transcriptase (RT) with a Ki value of 0.08 μM. It also exerts inhibitory effects on DNA polymerases α, β, and γ, with corresponding Ki values of 300 μM, 12 μM, and 112.25 μM. Demonstrating significant antiretroviral efficacy and favorable tolerability, Apricitabine shows a reduced potential for resistance development in patients with antiretroviral-naive HIV infection. This compound is applicable for research in the mechanisms of HIV-1 replication and antiviral drug development. -
HBV Inhibitor
HBV-IN-48 is a potent inhibitor of Hepatitis B Virus (HBV) with demonstrated antiviral activity. It effectively reduces viral replication in HepDE19 cells, achieving an EC50 value of 0.005 μM. Additionally, HBV-IN-48 has shown the ability to lower serum HBV DNA levels in mouse models, making it a valuable tool for studying HBV infections and potential therapeutic interventions. -
DENV Inhibitor
DENV-IN-4 is a potent inhibitor of Dengue Virus (DENV), exhibiting an EC50 value of 4.79 µM in Vero cells with a selectivity index greater than 20.9. This compound effectively reduces the expression levels of DENV2 in a concentration-dependent manner and inhibits RNA-dependent RNA polymerase (RdRp) enzymatic activity. DENV-IN-4 is valuable for research applications focused on understanding DENV pathogenesis and developing antiviral therapies. -
HBV DNA Synthesis Inhibitor
LB80317 is an active metabolite of LB80380 that functions as a potent inhibitor of HBV DNA synthesis, exhibiting an EC50 of 0.5 μM. This compound demonstrates antiviral activity, making it a promising candidate for the treatment of chronic hepatitis B. Its ability to inhibit viral replication supports its potential utility in HBV research and therapeutic applications. -
DNA Gyrase Inhibitor
DNA Gyrase-IN-11 is a selective inhibitor of DNA gyrase, targeting bacterial DNA replication and supercoiling mechanisms. It demonstrates a potent inhibitory effect on protein synthesis with an IC50 of 0.74 μM and effectively inhibits E. coli DNA gyrase with an IC50 of 11.9 μM. Additionally, DNA Gyrase-IN-11 possesses significant antibacterial activity against pathogens such as Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Staphylococcus aureus, with minimum inhibitory concentrations (MICs) ranging from 0.008 to 0.25 μg/mL, making it a valuable tool for antimicrobial research. -
HBV Inhibitor
HBV-IN-21 is a potent inhibitor of hepatitis B virus (HBV) DNA replication, exhibiting an IC50 of 2.2 µM. This compound demonstrates a strong interaction with the HBV core capsid protein, characterized by a dissociation constant (KD) of 60.0 μM. HBV-IN-21 is suited for research applications focused on antiviral drug development and elucidation of HBV replication mechanisms. -
DNA Synthesis/HSV/HIV-1 Inhibitor
16,16-Dimethyl prostaglandin A1 is a prostaglandin analog that primarily inhibits DNA synthesis. It demonstrates significant antiviral activity by reducing viral replication in both herpes simplex virus (HSV) and HIV-1 infection models. This compound serves as a valuable tool for research focused on cancer biology and viral pathogenesis. -
DENV/ZIKV Inhibitor
Antiviral agent 36 is a potent inhibitor of dengue virus (DENV) and Zika virus (ZIKV), demonstrating effective antiviral activity. It inhibits viral replication with EC50 values of 100 nM for ZIKV-FLR, 90 nM for ZIKV-HN16, 210 nM for DENV-2, and 120 nM for DENV-3. This compound serves as a valuable tool for research focused on the therapeutic development and understanding of DENV and ZIKV infections. -
SARS-CoV-2 RdRp Inhibitor
RdRP-IN-10 is a selective inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), exhibiting an IC50 of 5.78 μM. This compound covalently binds to Cys114 of the SARS-CoV-2 nsp8 protein, disrupting the stabilizing interactions between nsp8 and nsp12. RdRP-IN-10 effectively inhibits RNA polymerization mediated by RdRp without interfering with the RNA-RdRp complex formation. It demonstrates antiviral activity in cellular models and serves as a valuable tool for researching SARS-CoV-2 infection mechanisms and potential therapeutic interventions. -
DENV Inhibitor
DENV-IN-7 is a flavone analog that functions as a dengue virus (DENV) inhibitor, demonstrating an EC50 value of 70 nM. This compound exhibits low toxicity to normal cells while maintaining effective antiviral activity against DENV. It is suitable for research applications focused on the development of therapeutics for dengue virus infections. -
Bacterial DNA Gyrase/Topo IV Inhibitor
GC-072 is a selective inhibitor of bacterial DNA gyrase and Topoisomerase IV, demonstrating potent antibacterial activity. This 4-oxoquinolizine antibiotic exhibits efficacy against a wide range of bacterial strains, including Gram-positive, Gram-negative, and multidrug-resistant organisms. Importantly, GC-072 does not interfere with human topoisomerases I and II, making it a suitable candidate for studying bacterial infections. Its bactericidal action against Burkholderia pseudomallei is significant, as it supports dose-dependent survival rates in mice during lethal inhalational models, highlighting its potential in melioidosis research. -
HIV-1 Reverse Transcriptase Inhibitor
R82913 (9-Cl-TIBO) is a selective inhibitor of HIV-1 reverse transcriptase, demonstrating significant antiviral activity against both RNA and DNA templates crucial for viral replication. This compound effectively inhibits the replication of various HIV-1 strains in CEM cells, with a median IC50 value of 0.15 μM. It serves as a valuable reagent for research applications focused on HIV therapy development and reverse transcriptase inhibition studies. -
Bacterial DNA Gyrase B Inhibitor
DNA Gyrase-IN-3 is a specific inhibitor of bacterial DNA gyrase B, exhibiting IC50 values ranging from 5.41 to 15.64 µM against E. coli DNA gyrase. This compound demonstrates significant anti-tubercular and antibacterial activity, making it a valuable tool for microbial research. Its mechanism of action is relevant in studies aimed at developing new antibacterial agents targeting bacterial DNA replication and transcription processes. -
Bacterial Inhibitor
CI-990 (PD-131112) is a selective inhibitor of bacterial DNA gyrase, targeting key enzymes involved in DNA replication and repair. It exhibits potent antibacterial activity and is especially relevant for studying Enterococcal infections, including endocarditis and sepsis. This compound can serve as a valuable tool in microbiological research to understand bacterial resistance mechanisms and develop therapeutic strategies. -
EV71 3D Polymerase Inhibitor
DTriP-22 is a potent inhibitor of the enterovirus 71 (EV71) 3D polymerase, characterized by low toxicity. It demonstrates broad-spectrum antiviral activity against RNA viruses, particularly within the picornavirus family, while exhibiting no effects on DNA viruses. By targeting and inhibiting viral RNA synthesis during the early stages of replication, DTriP-22 serves as a valuable reagent in anti-enterovirus research applications. -
Dengue Viral Replication Inhibitor
DENV-IN-2 is a potent inhibitor of dengue viral replication, demonstrating exceptional activity against all four serotypes of the dengue virus. With an EC50 ranging from 0.013 to 0.029 nM, it shows remarkable efficacy in suppressing viral activity. This compound is valuable for research applications targeting dengue virus pathogenesis and developing antiviral strategies. -
HBV Inhibitor
HBV-IN-22 is a potent inhibitor of Hepatitis B Virus (HBV) DNA replication, demonstrating IC50 values of 0.71 μM against wild-type strains and 0.84 μM against resistant strains. This compound is valuable for research focused on antiviral drug development and understanding HBV resistance mechanisms, making it a critical tool in the study of Hepatitis B therapeutics. -
Bacterial Transcription Inhibitor
CUHK242 is a selective bacterial transcription inhibitor that effectively disrupts RNA synthesis within bacterial cells. It demonstrates a minimum inhibitory concentration (MIC) of 2 μg/mL against the B. subtilis reporter strain BS2019 and exhibits antimicrobial activity against Staphylococcus aureus. This compound is useful for research applications focused on understanding bacterial gene expression and studying the mechanisms of antibiotic resistance. -
DENV Inhibitor
DENV-IN-6 is a powerful inhibitor of dengue virus (DENV) serotypes I-IV, exhibiting effective antiviral activity with EC50 values of 17.5, 13.20, 6.8, and 11.41 μM, respectively, for the inhibition of viral replication. Additionally, DENV-IN-6 demonstrates notable activity against HIV-1 IIIB, with an EC50 of 0.0181 µM and a cytotoxicity (CC50) of 64.92 µM. This compound serves as a valuable tool for research into antiviral therapies targeting DENV and HIV-1. -
HIV Inhibitor
Fozivudine tidoxil is an orally active HIV inhibitor designed as a thioether lipid-zidovudine (ZDV) conjugate. This compound exhibits potent anti-HIV activity by incorporating into the newly synthesized DNA strand during viral replication, leading to irreversible binding to viral reverse transcriptase and disruption of the reverse transcription process. In addition to its antiviral properties, Fozivudine tidoxil is also a versatile click chemistry reagent, capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with suitable alkyne or DBCO/BCN-containing molecules, making it valuable for chemical biology applications. -
HIV-1 Inhibitor
HIV-1 Inhibitor-43 is a selective inhibitor targeting the HIV-1 virus. It demonstrates potent efficacy with an EC50 of 21.3 nM for Y188L mutants, 6.2 nM for K103N-Y181C, and under 0.7 nM for both K103N and Y181C strains. This compound effectively reduces HIV-1 RNA levels and protein p24 expression, making it a valuable tool for research in HIV pathogenesis and therapeutic development. -
DENV/HIV-1 Inhibitor
DENV-IN-5 is a potent inhibitor targeting both dengue virus (DENV) and HIV-1 replication. It demonstrates effective antiviral activity with half-maximal effective concentration (EC50) values of 1.47, 9.23, 7.08, and 8.91 μM against DENV serotypes I to IV, respectively. Additionally, DENV-IN-5 inhibits the HIV-1 IIIB strain with an EC50 of 0.1512 μM. This compound is valuable for research focused on viral infections and the development of antiviral therapies. -
Bacterial DNA Gyrase B Inhibitor
DNA Gyrase-IN-2 is a potent inhibitor of bacterial DNA gyrase B, demonstrating IC50 values of 3.29-10.49 µM for Escherichia coli and 4.41-5.61 µM for Mycobacterium tuberculosis. This compound exhibits significant anti-tubercular and antibacterial activity, making it valuable for research focused on bacterial replication and antibiotic development. Its specific targeting of DNA gyrase B positions it as a promising candidate for further investigation in treating bacterial infections. -
HIV/HBV Inhibitor
L-2'-Fd4C is an L-nucleoside analogue that acts as an inhibitor of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV). This compound exhibits potent antiviral activity, making it valuable for research focused on the treatment and understanding of these viral infections. Its unique mechanism of action may provide insights into the development of novel therapeutic strategies against HIV and HBV. -
RdRP Inhibitor
RdRP-IN-3 is an inhibitor of RNA-dependent RNA polymerase (RdRp), providing a potent approach for antiviral research against influenza viruses. This compound effectively disrupts RdRp activity, thereby hindering viral replication and proliferation. It serves as a valuable tool in studying the mechanisms of influenza pathogenesis and evaluating potential antiviral therapies. -
DENV NS5 RdRp Inhibitor
3'-Deoxy-GTP (3′-Deoxyguanosine 5′-triphosphate) is a nucleotide analog that serves as a potent inhibitor of DENV NS5 RNA-dependent RNA polymerase (RdRp). Functioning as a chain terminator, it effectively suppresses RNA synthesis, making it a valuable tool in virology research. With an IC50 of 0.02 μM against DENV NS5 RdRp, this compound is crucial for studies focusing on antiviral mechanisms and the development of therapeutic strategies targeting dengue virus infections. -
HBV Inhibitor
HBV-IN-53 is an inhibitor of Hepatitis B virus (HBV) that effectively reduces serum levels of HBV DNA. Its potent antiviral activity makes it a valuable tool for research in HBV therapeutics. Additionally, HBV-IN-53 has been shown to exhibit an additive inhibitory effect when combined with Tenofovir disoproxil fumarate, highlighting its potential for use in combination therapy studies. -
HIV-1 Inhibitor
SJP-L-5 is an HIV-1 capsid dissociation inhibitor that targets the HIV-1 viral capsid, preventing its normal function. It demonstrates significant inhibitory activity against various HIV-1 strains, with an EC50 ranging from 0.16 to 0.97 μg/mL. By effectively blocking the entry of HIV-1 viral DNA into the nucleus, SJP-L-5 offers valuable potential for applications in HIV-1 infection research and development of antiviral therapies. -
RSV RdRp Inhibitor
GS-646089 is a potent inhibitor of respiratory syncytial virus (RSV) RNA-dependent RNA polymerase (RdRp). This broad-spectrum antiviral nucleoside analog demonstrates robust activity against RSV, human metapneumovirus (hMPV), rhinovirus, and enteroviruses, with an IC50 in the range of 43 to 46 nM. GS-646089 is converted intracellularly into a triphosphate metabolite that competes with ATP for incorporation into growing RNA chains, effectively terminating viral replication. This compound serves as a valuable tool for research into acute respiratory viral infections and related viral pathogens. -
HSV Inhibitor
Abyssinone V is a prenylated flavonoid recognized for its antiviral properties, specifically as an inhibitor of herpes simplex virus (HSV). Isolated from the stem bark of Erythrina melanacantha, Abyssinone V exhibits favorable pharmacodynamic characteristics. Its mechanisms of action include the inhibition of viral polymerase, ATPase activity, and disruption of membrane integrity, making it a valuable compound for research into HSV-related therapies. -
RNA Polymerase Inhibitor
RNA polymerase-IN-4 is a potent inhibitor of RNA polymerase, exhibiting an EC50 of 22.81 nM. This compound demonstrates significant anti-influenza virus activity with an EC50 of 3.76 nM and displays relatively low cytotoxicity, with a CC50 of 29.91 μM. RNA polymerase-IN-4 is suitable for research applications focused on viral infections, particularly those related to influenza virus. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-115 is a potent inhibitor of SARS-CoV-2, demonstrating significant antiviral activity in infected Calu-3 cells with an EC50 of 1.7 μM. This compound effectively inhibits human dihydroorotate dehydrogenase (HsDHODH) with an IC50 of 1.5 μM. Notably, SARS-CoV-2-IN-115 preserves immune response without exhibiting antiproliferative effects on CD4 T cells, making it a valuable tool for research in antiviral therapeutics and immune modulation. -
CMV Inhibitor
Soyasaponin II is a saponin known for its antiviral properties, particularly as an inhibitor of cytomegalovirus (CMV) replication. It demonstrates strong efficacy against various viruses, including HSV-1, HCMV, influenza, and HIV-1. Additionally, Soyasaponin II inhibits YB-1 phosphorylation and NLRP3 inflammasome priming, offering potential protective effects in models of acute liver failure induced by LPS/GalN. This compound is valuable for research in virology and inflammation. -
RSV Inhibitor
CL-A3-7 is a potent respiratory syncytial virus (RSV) inhibitor that targets the RSV F protein, functioning as a virus-cell fusion inhibitor. By disrupting the interaction between the virus and the host insulin-like growth factor 1 receptor (IGF1R), CL-A3-7 effectively prevents infections caused by both wild-type RSV and the K394R variant. This compound is valuable for use in anti-RSV drug development and studies focused on resistance mechanisms associated with RSV. -
HIV-Ⅰ Inhibitor
HIV-IN-6 is an inhibitor of HIV-1 viral replication, specifically targeting Src family kinases (SFKs) that associate with the viral Nef protein, including Hck. This compound has demonstrated significant antiviral activity by disrupting the functional interactions necessary for viral pathogenesis. Its application in research includes the study of HIV infection mechanisms and the exploration of novel therapeutic strategies against HIV-1. -
Dyrk1A Inhibitor
Dyrk1A-IN-12 is a selective inhibitor of Dual specificity tyrosine phosphorylation regulated kinase 1A (Dyrk1A), demonstrating an IC50 of 95 nM. This compound exhibits significant anti-Enterovirus A71 (EV-A71) activity, with an EC50 of 4.4 μM and a cytotoxicity CC50 of 12.8 μM, resulting in a selectivity index of 2.9. Additionally, Dyrk1A-IN-12 shows strong inhibitory effects against herpes simplex virus (HSV), positioning it as a valuable tool for research in viral infections and Dyrk1A-related pathways. -
BTK/MNK Dual Inhibitor
QL-X-138 is a selective dual inhibitor of Bruton's tyrosine kinase (BTK) and MAPK-interacting kinase (MNK), demonstrating potent covalent binding to BTK and non-covalent binding to MNK. It exhibits IC50 values of 9.4 nM for BTK, and 107.4 nM and 26 nM for MNK1 and MNK2, respectively. Additionally, QL-X-138 displays antiviral activity against dengue virus serotype 2, with an IC50 of 3.5 μM. This compound is valuable for research involving B-cell malignancies and related therapeutic investigations. -
HIV Protease inhibitor
Atazanavir is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). -
HIV Protease inhibitor
Atazanavir is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). -
Protein synthesis inhibitor
Azomycin(2-Nitroimidazole) is an antimicrobial antibiotic produced by a strain of Nocardia mesenterica, which is active against aerobic Gram-positive and Gram-negative bacteria. -
HIV-1 integrase inhibitor
BMS-707035 is an HIV-1 integrase (IN) inhibitor. HIV-1 integrase (IN) represents a therapeutically advantageous viral target to treat HIV/AIDS in the clinic.
-
Dihydropyrimidinase Inhibitor
Dihydromyricetin (Ampelopsin (flavanol); Ampeloptin) is a natural antioxidant with good prospects.
